296 related articles for article (PubMed ID: 22431750)
21. Molecular mechanisms responsible for aberrant splicing of SERCA1 in myotonic dystrophy type 1.
Hino S; Kondo S; Sekiya H; Saito A; Kanemoto S; Murakami T; Chihara K; Aoki Y; Nakamori M; Takahashi MP; Imaizumi K
Hum Mol Genet; 2007 Dec; 16(23):2834-43. PubMed ID: 17728322
[TBL] [Abstract][Full Text] [Related]
22. Systemic delivery of a Peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophy.
Leger AJ; Mosquea LM; Clayton NP; Wu IH; Weeden T; Nelson CA; Phillips L; Roberts E; Piepenhagen PA; Cheng SH; Wentworth BM
Nucleic Acid Ther; 2013 Apr; 23(2):109-17. PubMed ID: 23308382
[TBL] [Abstract][Full Text] [Related]
23. Targeting toxic RNAs that cause myotonic dystrophy type 1 (DM1) with a bisamidinium inhibitor.
Wong CH; Nguyen L; Peh J; Luu LM; Sanchez JS; Richardson SL; Tuccinardi T; Tsoi H; Chan WY; Chan HY; Baranger AM; Hergenrother PJ; Zimmerman SC
J Am Chem Soc; 2014 Apr; 136(17):6355-61. PubMed ID: 24702247
[TBL] [Abstract][Full Text] [Related]
24. Sense and Antisense DMPK RNA Foci Accumulate in DM1 Tissues during Development.
Michel L; Huguet-Lachon A; Gourdon G
PLoS One; 2015; 10(9):e0137620. PubMed ID: 26339785
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy.
Bisset DR; Stepniak-Konieczna EA; Zavaljevski M; Wei J; Carter GT; Weiss MD; Chamberlain JR
Hum Mol Genet; 2015 Sep; 24(17):4971-83. PubMed ID: 26082468
[TBL] [Abstract][Full Text] [Related]
26. Aberrantly spliced alpha-dystrobrevin alters alpha-syntrophin binding in myotonic dystrophy type 1.
Nakamori M; Kimura T; Kubota T; Matsumura T; Sumi H; Fujimura H; Takahashi MP; Sakoda S
Neurology; 2008 Feb; 70(9):677-85. PubMed ID: 18299519
[TBL] [Abstract][Full Text] [Related]
27. Alternative splicing of myomesin 1 gene is aberrantly regulated in myotonic dystrophy type 1.
Koebis M; Ohsawa N; Kino Y; Sasagawa N; Nishino I; Ishiura S
Genes Cells; 2011 Sep; 16(9):961-72. PubMed ID: 21794030
[TBL] [Abstract][Full Text] [Related]
28. A flow cytometry-based screen identifies MBNL1 modulators that rescue splicing defects in myotonic dystrophy type I.
Zhang F; Bodycombe NE; Haskell KM; Sun YL; Wang ET; Morris CA; Jones LH; Wood LD; Pletcher MT
Hum Mol Genet; 2017 Aug; 26(16):3056-3068. PubMed ID: 28535287
[TBL] [Abstract][Full Text] [Related]
29. Defining early steps in mRNA transport: mutant mRNA in myotonic dystrophy type I is blocked at entry into SC-35 domains.
Smith KP; Byron M; Johnson C; Xing Y; Lawrence JB
J Cell Biol; 2007 Sep; 178(6):951-64. PubMed ID: 17846170
[TBL] [Abstract][Full Text] [Related]
30. Rationally designed small molecules targeting the RNA that causes myotonic dystrophy type 1 are potently bioactive.
Childs-Disney JL; Hoskins J; Rzuczek SG; Thornton CA; Disney MD
ACS Chem Biol; 2012 May; 7(5):856-62. PubMed ID: 22332923
[TBL] [Abstract][Full Text] [Related]
31. Muscleblind-like 1 knockout mice reveal novel splicing defects in the myotonic dystrophy brain.
Suenaga K; Lee KY; Nakamori M; Tatsumi Y; Takahashi MP; Fujimura H; Jinnai K; Yoshikawa H; Du H; Ares M; Swanson MS; Kimura T
PLoS One; 2012; 7(3):e33218. PubMed ID: 22427994
[TBL] [Abstract][Full Text] [Related]
32. Alternative splicing dysregulation secondary to skeletal muscle regeneration.
Orengo JP; Ward AJ; Cooper TA
Ann Neurol; 2011 Apr; 69(4):681-90. PubMed ID: 21400563
[TBL] [Abstract][Full Text] [Related]
33. CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1.
Ward AJ; Rimer M; Killian JM; Dowling JJ; Cooper TA
Hum Mol Genet; 2010 Sep; 19(18):3614-22. PubMed ID: 20603324
[TBL] [Abstract][Full Text] [Related]
34. Dysfunction of protein homeostasis in myotonic dystrophies.
Meola G; Jones K; Wei C; Timchenko LT
Histol Histopathol; 2013 Sep; 28(9):1089-98. PubMed ID: 23536431
[TBL] [Abstract][Full Text] [Related]
35. A novel CUG(exp)·MBNL1 inhibitor with therapeutic potential for myotonic dystrophy type 1.
Jahromi AH; Nguyen L; Fu Y; Miller KA; Baranger AM; Zimmerman SC
ACS Chem Biol; 2013 May; 8(5):1037-43. PubMed ID: 23480597
[TBL] [Abstract][Full Text] [Related]
36. Transgenic mice expressing CUG-BP1 reproduce splicing mis-regulation observed in myotonic dystrophy.
Ho TH; Bundman D; Armstrong DL; Cooper TA
Hum Mol Genet; 2005 Jun; 14(11):1539-47. PubMed ID: 15843400
[TBL] [Abstract][Full Text] [Related]
37. Defective mRNA in myotonic dystrophy accumulates at the periphery of nuclear splicing speckles.
Holt I; Mittal S; Furling D; Butler-Browne GS; Brook JD; Morris GE
Genes Cells; 2007 Sep; 12(9):1035-48. PubMed ID: 17825047
[TBL] [Abstract][Full Text] [Related]
38. Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy.
Kanadia RN; Shin J; Yuan Y; Beattie SG; Wheeler TM; Thornton CA; Swanson MS
Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11748-53. PubMed ID: 16864772
[TBL] [Abstract][Full Text] [Related]
39. MBNL1 overexpression is not sufficient to rescue the phenotypes in a mouse model of RNA toxicity.
Yadava RS; Kim YK; Mandal M; Mahadevan K; Gladman JT; Yu Q; Mahadevan MS
Hum Mol Genet; 2019 Jul; 28(14):2330-2338. PubMed ID: 30997488
[TBL] [Abstract][Full Text] [Related]
40. Gain of RNA function in pathological cases: Focus on myotonic dystrophy.
Klein AF; Gasnier E; Furling D
Biochimie; 2011 Nov; 93(11):2006-12. PubMed ID: 21763392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
